Amgen Czech Republic's net debt reached CZK -0.283 mil and accounted for -0.147% of equity at the end of 2017. The ratio is down 0.022 pp when compared to the previous year.
Historically, the firm’s net debt to equity reached a high of 38.7% in 2015 and a low of -80.1% in 2005 during the 2005 - 2017 period. The average for the last five years reached 11.4%.
When compared to EBITDA, net debt amounted to -0.006x at the end of the year. That is down from 0x seen in 2012. The ratio reached a high of 1.53x in 2015 and a low of -2.63x in 2008.
Company’s cost of funding amounted to in 2017, down when compared to the average seen in the last 5 years (475%). The funding costs have “eaten” some 0.69% of operating profit generated in 2019.
|Amgen Czech Republic||...||...||-0.005||0.709||1.53|
|Bayer Czech Republic||-0.298||-0.098||0.140||0.150||0.890|
|GlaxoSmithKline Czech Republic||0.438||1.02||1.69||-0.001||-3.71|
|Merck Czech Republic||1.87||1.39||2.80||0.353||-0.026|
|Novartis Czech Republic||3.22||0.696||-0.064||0.826||-0.015|
|Pfizer Czech Republic||2.16||-1.32||-0.141||-1.65||-0.037|
|Roche Czech Republic||-0.002||0.737||0.867||2.04||3.15||...|
|Sanofi-Aventis Czech Republic||12.8||16.5||8.87||27.7||4.27|
|Servier Czech Republic||...||...||-1.54||-2.09||-1.74||-0.839|